4.5 Review

A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living

期刊

NEUROLOGICAL SCIENCES
卷 43, 期 10, 页码 5821-5837

出版社

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-022-06159-9

关键词

Rotigotine transdermal patch; Parkinson's disease; Motor symptoms; ADL; Sleep disturbances; Adverse events

资金

  1. National Foundation of Natural Science of China [82074539, 81704170]
  2. Natural Science of Heilongjiang Province [LH2020H092]
  3. Research Fund Project for Chinese Medicine of Heilongjiang Province [ZHY202079]
  4. Research Fund for Construction of Evidence Based Medicine for Chinese Medicine [2019XZZX-ZJ005]
  5. Japan Society for the Promotion of Science [20791025, 24592157, 15k10358, 18K08991]

向作者/读者索取更多资源

This meta-analysis evaluated the effects of rotigotine transdermal patch (TP) on motor performance, activities of daily living (ADL) limitations, and sleep disturbances in patients with Parkinson's disease (PD). The results showed that rotigotine TP significantly improved movement symptoms, ADL limitations, and sleep quality without increasing adverse events. This study provides compelling evidence for the clinical usage of rotigotine TP.
Background Rotigotine transdermal patch (TP) is a useful dopaminergic medication for Parkinson's disease (PD). This meta-analysis attempted to evaluate the effects of rotigotine TP on motor performance, activities of daily living (ADL) limitations, and sleep disturbances in patients with PD. Methods Only randomized controlled clinical trials (RCTs) with placebo design were included in this study. The clinical outcomes, evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS III), UPDRS-II, UPDRS Part II + III, Parkinson's Disease Sleep Scale (PDSS)-2, and adverse events (AEs) were evaluated. The Jadad scale was used to evaluate study quality. Results A total of 16 RCTs with 4682 patients with PD were enrolled in this study. We found that rotigotine TP significantly reduced the UPDRS-III, UPDRS-II, and UPDRS Part II + III scores, indicating that rotigotine TP led to a significant amelioration of movement symptoms and ADL limitations. Moreover, we found that rotigotine TP significantly reduced PDSS-2 scores, suggesting that rotigotine TP led to a remarkable improvement in sleep quality. Meanwhile, compared with the placebo group, patients taking rotigotine TP did not have added incidence of AEs. Conclusion This study verified the efficacy and safety of rotigotine TP in treating PD. The findings of the present study provide compelling evidence concerning and insight into clinical usage of rotigotine TP. Future studies will focus on more non-motor symptoms affected by rotigotine TP.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据